Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Payables: 2009-2024

Historic Payables for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $31.2 million.

  • Northwest Biotherapeutics' Payables rose 58.67% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 67.15%. This contributed to the annual value of $31.2 million for FY2024, which is 119.59% up from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' Payables is $31.2 million, which was up 119.59% from $14.2 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Payables registered a high of $31.2 million during FY2024, and its lowest value of $9.8 million during FY2020.
  • For the 3-year period, Northwest Biotherapeutics' Payables averaged around $23.8 million, with its median value being $26.1 million (2022).
  • Per our database at Business Quant, Northwest Biotherapeutics' Payables slumped by 45.62% in 2023 and then soared by 119.59% in 2024.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Payables stood at $9.8 million in 2020, then soared by 43.42% to $14.1 million in 2021, then soared by 85.30% to $26.1 million in 2022, then tumbled by 45.62% to $14.2 million in 2023, then skyrocketed by 119.59% to $31.2 million in 2024.